Colombian foundation center for epilepsy and neurological disease Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2012
NCT01655927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Colombian foundation center for epilepsy and neurological disease -FIRE | Colombian foundation center for epilepsy and neurological disease - FIRE

Active Ingredients

Drugs in Phase 3 Trials (1)

tranexamic acid (cyklokapron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Brain Neoplasms (Phase 3)

Meningioma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1